Evidence map›Paper›PMID 22041323›Full record

Trial reportJournal of cardiac failure2011

Statins do not significantly affect muscle sympathetic nerve activity in humans with nonischemic heart failure: a double-blind placebo-controlled trial.

Tamara B Horwich, Holly R Middlekauff, W Robb Maclellan, Gregg C Fonarow

Open access · greenAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of cardiac failure, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 3 pooled it
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 3 syntheses or guidelines pooled it, 21 citations in OpenAlex.

  1. Effect of atorvastatin on testosterone levels.The Cochrane database of systematic reviews · 2021
    Pooled it
  2. Pooled it
  3. The effect of statins on sympathetic activity: a meta-analysis.Clinical autonomic research : official journal of the Clinical Autonomic Research Society · 2015
    Pooled it
  4. Statin therapy lowers muscle sympathetic nerve activity and oxidative stress in patients with heart failure.American journal of physiology. Heart and circulatory physiology · 2012
    Trial
  5. Review
  6. Hydrophilic or Lipophilic Statins?Frontiers in cardiovascular medicine · 2021
    Review
  7. Takotsubo cardiomyopathy a short review.Current cardiology reviews · 2013
    Review
  8. Statins in heart failure: do we need another trial?Vascular health and risk management · 2013
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Tamara B HorwichDivision of Cardiology, David Geffen School of Medicine, University of California, Los Angeles, California, USA. thorwich@mednet.ucla.edu
Holly R Middlekauff
W Robb Maclellan
Gregg C Fonarow
University of California, Los Angeles · US

Funding

ZDV &3TC NEVIRAPINE COMBINATION THERAPY IN HIV 1 INFECTED INFANTS &M01RR000865 · NCRR · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI WASHINGTON, ARNOLD E. · 1985 to 2011
$43.4M
Sympathetic Nerve Activity and the Skeletal Myopathy of Heart FailureR01HL084525 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI MIDDLEKAUFF, HOLLY R · 2007 to 2010
$1.5M
Statins in Non-Ischemic Heart Failure: Potential Mechanisms of BenefitK23HL085097 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI HORWICH, TAMARA BETH · 2007 to 2010
$432k
NCRR NIH HHS M01 RR000865NCRR NIH HHS MO1-RR00865NHLBI NIH HHS 1K23HL085097NHLBI NIH HHS K23 HL085097NHLBI NIH HHS R01 HL084525
6 · The paper itself

Abstract

backgroundHydroxymethylglutaryl-coenzyme A reductase inhibitors (statins) have been shown to reduce sympathetic nervous system (SNS) activation in experimental heart failure (HF). However, this potential mechanism of action of statins in HF has not been well studied in humans. METHODS AND

resultsTwenty-six patients with nonischemic systolic HF (left ventricular ejection fraction [LVEF] ≤35%) were randomized to atorvastatin (10 mg) or placebo for 3 months. Pre- and posttreatment testing included echocardiography, laboratory assays, quality of life (QOL) questionnaires, and peroneal nerve muscle sympathetic nerve activity (MSNA) via microneurography. Eighteen subjects had technically adequate MSNA tracings before and after treatment. The cohort was 65% male, 81% New York Heart Association functional class II, LVEF 26 ± 6%, and low-density lipoprotein cholesterol (LDL-C) 108 ± 26 mg/dL. Baseline MSNA was 41 ± 2 bursts/min. LDL-C significantly decreased in the atorvastatin (-36.8%) versus the placebo (-0.1%) group (P < .0001). However, there was no significant change in MSNA (-16.2% vs -2.5%), LVEF, B-type natriuretic peptide, or QOL score in the atorvastatin compared with the placebo group.

conclusionsShort-term statin therapy in patients with nonischemic HF does not result in a significant decrease in SNS activation as measured by MSNA. These findings are consistent with the neutral outcomes of large clinical trials of statins in HF.

Indexed as

Anticholesteremic AgentsAtorvastatinDouble-Blind MethodFemaleHeart FailureHeptanoic AcidsHumansHydroxymethylglutaryl-CoA Reductase InhibitorsMaleMiddle AgedPeroneal NervePyrrolesStroke VolumeSurveys and QuestionnairesSympathetic Nervous SystemTime FactorsAnticholesteremic AgentsAtorvastatinHeptanoic AcidsHydroxymethylglutaryl-CoA Reductase InhibitorsPyrroles

Identifiers

PMID22041323
PMCPMC3206298
OpenAlexW1977736384

What OpenQuestion holds

Texttitle and abstract
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.